CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Experimental cell therapy targets Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new treatment called PSMA-UCAR T cells for men with advanced prostate cancer that no longer responds to standard therapies. The therapy uses specially engineered immune cells to target a protein (PSMA) on cancer cells. The main goal is to check safe…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 26, 2026 03:22 UTC
-
DNA vaccine combo shows promise in Hard-to-Treat prostate cancer
Disease control OngoingThis study tests whether adding a second DNA vaccine to a standard immunotherapy (pembrolizumab) can better control advanced prostate cancer that no longer responds to hormone therapy. About 60 adults with metastatic, castration-resistant prostate cancer will receive either one o…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Wisconsin, Madison • Aim: Disease control
Last updated May 26, 2026 03:15 UTC
-
Bone drug breakthrough: could less be more for cancer patients?
Disease control OngoingThis study looks at whether people with breast or prostate cancer that has spread to the bones can safely stop or reduce their bone-strengthening medication after taking it for at least two years. The goal is to see if this approach maintains quality of life and prevents bone com…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE4 • Sponsor: Ottawa Hospital Research Institute • Aim: Disease control
Last updated May 26, 2026 02:49 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control OngoingThis early-phase trial tests a new treatment for men with a tough-to-treat form of advanced prostate cancer. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to check if the treatment is s…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Shanghai Changzheng Hospital • Aim: Disease control
Last updated May 18, 2026 12:03 UTC
-
New imaging agent aims to spot Hard-to-Find cancers
Diagnosis TerminatedThis study was designed to test a new imaging agent called 111In-ABD147 that targets a protein (DLL3) found on many solid tumors, including prostate cancer and neuroendocrine tumors. The goal was to see if it could help detect metastatic cancer using SPECT scans. However, the stu…
Matched conditions: CASTRATION-RESISTANT PROSTATE CANCER
Phase: EARLY_PHASE1 • Sponsor: Thomas Hope • Aim: Diagnosis
Last updated May 22, 2026 14:03 UTC